Diabetes drug liraglutide may fight fatty liver, but trial halted early
NCT ID NCT02721888
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study looked at whether liraglutide, a diabetes drug, can reduce liver fat and improve cholesterol in people with type 2 diabetes. It involved 127 patients who took liraglutide for 6 months, with liver fat measured by MRI. However, the trial was terminated early, so the full results are not available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- liraglutide
- What this could lead to
- If successful, this could show that liraglutide helps reduce liver fat and improve cholesterol levels in people with type 2 diabetes.
- What could go wrong
- The trial was terminated early, so results are incomplete. It was also a small, single-center study, so findings may not apply broadly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU de Dijon
Dijon, 21079, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Daily pill could offer new hope for weight loss in east asian adults
- Blood test could predict who faces rapid kidney decline in diabetes
- Blood test may predict kidney decline in diabetes — a large trial investigates
- Hormone clue may unmask kidney danger in diabetes
- Can a single pill tackle both fatty liver and diabetes?
- Does when you eat carbs and protein reshape blood sugar control?